Catalyst Wire Dossier Catalyst Wire Dossier

belatacept (active pharmaceutical ingredient from both Process E and Process C)

belatacept · Bristol-Myers Squibb
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for belatacept (active pharmaceutical ingredient from both Process E and Process C), covering 2019-04-17 to 2019-04-17. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Compare the Pharmacokinetics of Belatacept Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Process C [Phase 1]

See pricing